Good news! All CHIP, STAR, and STAR Kids Member Handbooks are now available online. Quick, easy access to your benefits and coverage information - any time!
¡Buenas noticias! Todos los manuales para miembros de CHIP, STAR y STAR Kids ya están disponibles en línea. Obtén acceso rápido y sencillo a la información sobre tus beneficios y cobertura, ¡en cualquier momento!
Medicaid Preferred Drug List and Formulary ChangesCambios en el formulario y la lista de medicamentos preferidos de Medicaid
The Vendor Drug Program (VDP) made changes to the Texas Medicaid drug formulary effective July 24, 2026. To learn more about formulary changes impacted, please click here for more information.
El programa de medicamentos de proveedores de Texas (VDP) ha realizado cambios recientes en el formulario de medicamentos de Medicaid de Texas. Esto entrará en vigencia el 24 de julio de 2026. Para obtener más información sobre los cambios en el formulario afectados, visite el siguiente enlace para obtener más información.
Date: October 12, 2022 Attention: All Providers Effective Date: August 31, 2022Providers should monitor the Texas Children’s Health Plan (TCHP) Provider Portal regularly for alerts and updates associated to the COVID-19 event. TCHP reserves the right to update and/or change this information without prior notice due to the evolving nature of the COVID-19 event.
Call to action: Texas Children’s Health Plan’s (TCHP) would like to notify providers that on August 31, 2022, the U.S. Food and Drug Administration (FDA) amended the Emergency Use Authorizations (EUAs) for the Pfizer-BioNTech COVID-19 vaccine to authorize a new, bivalent formulation designed to stimulate immunity to both the original strain of SARS-CoV-2 virus and the omicron variant.
The new, bivalent Pfizer-BioNTech COVID-19 booster vaccine is authorized for individuals 12 years and older.
The new vaccine formulation is not intended for use as either of the doses in the primary series.
It should be administered as a single booster dose at least two months following completion of either a primary series of COVID-19 vaccines or monovalent booster vaccination.
How this impacts providers: TCHP wants providers to be aware that HHSC allows for pharmacy benefit coverage of the new, bivalent Pfizer-BioNTech COVID-19 booster vaccine in compliance with the EUA issued by the FDA.
Providers should educate eligible TCHP members about the health benefits of preventing COVID-19 infection and make TCHP members aware of increased access to this booster vaccine at a participating pharmacy.
Effective August 31, 2022, HHSC will cover the new, bivalent Pfizer-BioNTech COVID-19 booster vaccine National Drug Codes (NDCs) in the table below for Medicaid and CHIP as a payable pharmacy benefit:
